Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Calcifediol - OPKO Renal/Vifor Fresenius Medical Care Renal Pharma

X
Drug Profile

Calcifediol - OPKO Renal/Vifor Fresenius Medical Care Renal Pharma

Alternative Names: Calcifediol extended release - OPKO Renal/Vifor Fresenius Medical Care Renal Pharma; CTAP-101; CTAP101 Capsules; JTT-762; Modified-release calcifediol - OPKO Renal/Vifor Fresenius Medical Care Renal Pharma; RAYALDEE; Rayaldee; Rayaldy

Latest Information Update: 11 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytochroma
  • Developer OPKO Health; OPKO Renal; Vifor Fresenius Medical Care Renal Pharma
  • Class Antivirals; Calcium regulators; Osteoporosis therapies; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Secondary hyperparathyroidism
  • Phase II COVID 2019 infections; Cystic fibrosis
  • No development reported Bone disorders

Most Recent Events

  • 11 Dec 2023 Phase-II clinical trials in Cystic fibrosis in USA (unspecified route) (OPKO Renal pipeline, December 2023)
  • 24 Feb 2023 Phase-III clinical trials in Secondary hyperparathyroidism (In adolescents, In children) in USA (PO) (NCT05543928)
  • 16 Sep 2022 OPKO Health plans a phase III trial for Secondary hyperparathyroidism (In children, in adolescents) (PO, Capsule) in October 2022 (NCT05543928)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top